Immunome, Inc. Operating Cash Flow
Immunome, Inc. (IMNM) reported Operating Cash Flow of -$120.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Immunome, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$61.69M.
- Immunome, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$58.64M.
- Immunome, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$47.95M.
- Immunome, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$40.51M.
- Immunome, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$190.92M.
- Immunome, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$110.79M.
- Immunome, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$7.57M.
- Immunome, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$28.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$61.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$120.33M 10-Q · filed 2026-08-11 | -$168.28M derived: sum of 3 quarters · filed 2026-08-11 | -$208.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$58.64M 10-Q · filed 2026-05-12 | -$106.59M derived: sum of 2 quarters · filed 2026-05-12 | -$147.10M derived: sum of 3 quarters · filed 2026-05-12 | -$196.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$47.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$88.46M derived: sum of 2 quarters · filed 2026-03-03 | -$137.86M derived: sum of 3 quarters · filed 2026-08-11 | -$190.92M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$40.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$89.91M derived: sum of 2 quarters · filed 2026-08-11 | -$142.97M 10-Q · filed 2025-11-06 | -$185.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$49.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$102.46M 10-Q · filed 2026-08-11 | -$144.52M derived: sum of 3 quarters · filed 2026-08-11 | -$178.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$53.05M 10-Q · filed 2026-05-12 | -$95.11M derived: sum of 2 quarters · filed 2026-05-12 | -$129.28M derived: sum of 3 quarters · filed 2026-05-12 | -$152.68M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$42.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$76.23M derived: sum of 2 quarters · filed 2026-03-03 | -$99.62M derived: sum of 3 quarters · filed 2026-03-03 | -$110.79M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$34.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$57.56M derived: sum of 2 quarters · filed 2025-11-06 | -$68.73M 10-Q · filed 2025-11-06 | -$86.19M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$23.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$34.57M 10-Q · filed 2025-08-06 | -$52.03M derived: sum of 3 quarters · filed 2025-08-06 | -$60.64M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$11.17M 10-Q · filed 2025-05-12 | -$28.63M derived: sum of 2 quarters · filed 2025-05-12 | -$37.24M derived: sum of 3 quarters · filed 2025-05-12 | -$42.91M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$17.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$26.07M derived: sum of 2 quarters · filed 2025-03-19 | -$31.74M derived: sum of 3 quarters · filed 2025-03-19 | -$7.57M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$8.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$14.28M derived: sum of 2 quarters · filed 2024-11-13 | $9.89M 10-Q · filed 2024-11-13 | $3.21M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$5.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $18.50M 10-Q · filed 2024-08-12 | $11.82M derived: sum of 3 quarters · filed 2024-08-12 | $4.25M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $24.17M 10-Q · filed 2024-05-14 | $17.49M derived: sum of 2 quarters · filed 2024-05-14 | $9.92M derived: sum of 3 quarters · filed 2024-05-14 | $1.86M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$14.25M derived: sum of 2 quarters · filed 2024-03-28 | -$22.31M derived: sum of 3 quarters · filed 2024-03-28 | -$28.69M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$7.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$15.63M derived: sum of 2 quarters · filed 2023-11-09 | -$22.01M 10-Q · filed 2023-11-09 | -$28.81M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$8.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$14.44M 10-Q · filed 2023-08-09 | -$21.24M derived: sum of 3 quarters · filed 2023-08-09 | -$25.39M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$6.38M 10-Q · filed 2023-05-05 | -$13.18M derived: sum of 2 quarters · filed 2023-05-05 | -$17.33M derived: sum of 3 quarters · filed 2023-05-05 | -$21.07M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | -$6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$10.95M derived: sum of 2 quarters · filed 2023-03-16 | -$14.69M derived: sum of 3 quarters · filed 2023-03-16 | -$18.23M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$4.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$7.89M derived: sum of 2 quarters · filed 2022-11-14 | -$11.42M 10-Q · filed 2022-11-14 | -$17.48M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$7.28M 10-Q · filed 2022-08-05 | -$13.34M derived: sum of 3 quarters · filed 2022-08-05 | -$15.87M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$3.54M 10-Q · filed 2022-05-12 | -$9.60M derived: sum of 2 quarters · filed 2022-05-12 | -$12.13M derived: sum of 3 quarters · filed 2022-05-12 | -$13.61M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$8.59M derived: sum of 2 quarters · filed 2022-03-28 | -$10.07M derived: sum of 3 quarters · filed 2022-03-28 | -$12.13M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$4.01M derived: sum of 2 quarters · filed 2021-11-15 | -$6.07M 10-Q · filed 2021-11-15 | -$8.65M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$3.54M 10-Q · filed 2021-08-16 | -$6.12M derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | -$2.06M 10-Q · filed 2021-05-12 | -$4.64M derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | -$2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$9.60M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$7.02M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |